A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors

NCT04431726 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Severe Hemophilia A

Interventions

DRUG: Emicizumab

Sponsor

Hoffmann-La Roche